{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:36:41Z","timestamp":1792705001314,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.advms.2019.02.005","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T03:17:18Z","timestamp":1553570238000},"page":"280-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Can hepatokines be regarded as novel non-invasive serum biomarkers of intrahepatic lipid content in obese children?"],"prefix":"10.1016","volume":"64","author":[{"given":"Marta","family":"Flisiak-Jackiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bobrus-Chociej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6327-8526","authenticated-orcid":false,"given":"Natalia","family":"Wasilewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeniusz","family":"Tarasow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Wojtkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz Marek","family":"Lebensztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.advms.2019.02.005_bib0005","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/MPG.0b013e318252a13f","article-title":"Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee","volume":"54","author":"Vajro","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.advms.2019.02.005_bib0010","first-page":"3082","article-title":"Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk","volume":"17","author":"Pacifico","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.advms.2019.02.005_bib0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/ars.2010.3848","article-title":"Adipokines and redox signaling: impact on fatty liver disease","volume":"15","author":"Parola","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.advms.2019.02.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/320724","article-title":"Adipo-myokines: two sides of the same coin \u2013 mediators of inflammation and mediators of exercise","author":"Reschke","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.advms.2019.02.005_bib0025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrendo.2012.258","article-title":"The role of hepatokines in metabolism","volume":"9","author":"Stefan","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.advms.2019.02.005_bib0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.18388\/abp.2016_1252","article-title":"Hepatokines and non-alcoholic fatty liver disease","volume":"63","author":"Lebensztejn","year":"2016","journal-title":"Acta Biochim Pol"},{"issue":"1","key":"10.1016\/j.advms.2019.02.005_bib0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.advms.2013.08.003","article-title":"Serum fetuin A concentration is elevated in children with non-alcoholic fatty liver disease","volume":"59","author":"Lebensztejn","year":"2014","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.advms.2019.02.005_bib0040","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.advms.2019.02.005_bib0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.292.6512.13","article-title":"Ultrasound scanning in the detection of hepatic fibrosis and steatosis","volume":"292","author":"Saverymuttu","year":"1986","journal-title":"Br Med J"},{"key":"10.1016\/j.advms.2019.02.005_bib0050","first-page":"36","article-title":"MR proton spectroscopy in liver examination of healthy individuals in vivo","volume":"8","author":"Taras\u00f3w","year":"2002","journal-title":"Med Sci Monit"},{"issue":"10","key":"10.1016\/j.advms.2019.02.005_bib0055","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2362.2010.02338.x","article-title":"Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease","volume":"40","author":"Yilmaz","year":"2010","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.advms.2019.02.005_bib0060","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","article-title":"Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride","volume":"53","author":"Li","year":"2010","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.advms.2019.02.005_bib0065","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jhep.2012.10.029","article-title":"High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China","volume":"58","author":"Li","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.advms.2019.02.005_bib0070","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jhep.2011.12.025","article-title":"Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers","volume":"56","author":"Shen","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.advms.2019.02.005_bib0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1475-2840-12-124","article-title":"Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease","volume":"12","author":"Shen","year":"2013","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.advms.2019.02.005_bib0080","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1210\/jc.2012-1221","article-title":"Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis","volume":"97","author":"Reinehr","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.advms.2019.02.005_bib0085","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1210\/jc.2013-1250","article-title":"Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage","volume":"98","author":"Giannini","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.advms.2019.02.005_bib0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4172\/2155-9899.1000393","article-title":"Role of serum biomarkers in early detection of non-alcoholic steatohepatitis and fibrosis in West Virginian children","volume":"7","author":"Sodhi","year":"2016","journal-title":"J Clin Cell Immunol"},{"issue":"6","key":"10.1016\/j.advms.2019.02.005_bib0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067160","article-title":"Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease","volume":"8","author":"Alisi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.advms.2019.02.005_bib0100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4093\/dmj.2013.37.1.63","article-title":"Increased selenoprotein P levels in subjects with visceral obesity and nonalcoholic fatty liver disease","volume":"37","author":"Choi","year":"2013","journal-title":"Diabetes Metab J"},{"issue":"3","key":"10.1016\/j.advms.2019.02.005_bib0105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF03401306","article-title":"Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease","volume":"12","author":"Polyzos","year":"2013","journal-title":"Hormones"},{"issue":"6","key":"10.1016\/j.advms.2019.02.005_bib0110","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/cen.12360","article-title":"Low serum sex hormone-binding globulin is associated with nonalcoholic fatty liver disease in type 2 diabetic patients","volume":"80","author":"Hua","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.advms.2019.02.005_bib0115","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1248\/bpb.b18-00046","article-title":"Comparison of human Selenoprotein P determinants in serum between our original methods and commercially available kits","volume":"41","author":"Saito","year":"2018","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.advms.2019.02.005_bib0120","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jmri.1880050311","article-title":"Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis","volume":"5","author":"Longo","year":"1995","journal-title":"J Magn Reson Imaging"},{"issue":"9","key":"10.1016\/j.advms.2019.02.005_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024895","article-title":"Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study","volume":"6","author":"Yan","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.advms.2019.02.005_bib0130","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jdi.12093","article-title":"Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: role of adipokines","volume":"4","author":"Hui","year":"2013","journal-title":"J Diabetes Invest"},{"issue":"3","key":"10.1016\/j.advms.2019.02.005_bib0135","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.metabol.2014.11.009","article-title":"The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy","volume":"64","author":"Liu","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.advms.2019.02.005_bib0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.mce.2011.05.003","article-title":"The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes","volume":"342","author":"Zhang","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.advms.2019.02.005_bib0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mce.2011.07.026","article-title":"The effects of fibroblast growth factor-21 knockdown and over-expression on its signaling pathway and glucose-lipid metabolism in vitro","volume":"348","author":"Li","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"10.1016\/j.advms.2019.02.005_bib0150","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.metabol.2014.04.011","article-title":"Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosis","volume":"63","author":"Lee","year":"2014","journal-title":"Metab Clin Exp"},{"issue":"6","key":"10.1016\/j.advms.2019.02.005_bib0155","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clinbiochem.2014.12.024","article-title":"Laboratory assessment of cardiometabolic risk in overweight and obese children","volume":"48","author":"Sypniewska","year":"2015","journal-title":"Clin Biochem"},{"key":"10.1016\/j.advms.2019.02.005_bib0160","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPAR alpha and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"Badman","year":"2007","journal-title":"Cell Metab"},{"key":"10.1016\/j.advms.2019.02.005_bib0165","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.advms.2019.02.005_bib0170","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1139\/h2012-091","article-title":"Modulating fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric restriction","volume":"37","author":"Fletcher","year":"2012","journal-title":"Appl Physiol Nutr Metab"},{"issue":"3","key":"10.1016\/j.advms.2019.02.005_bib0175","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MPG.0000000000000632","article-title":"Liver biopsy in children: position paper of the ESPGHAN Hepatology Committee","volume":"60","author":"Dezofi","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S189611261830230X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S189611261830230X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:41:11Z","timestamp":1761824471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S189611261830230X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S189611261830230X"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2019.02.005","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can hepatokines be regarded as novel non-invasive serum biomarkers of intrahepatic lipid content in obese children?","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2019.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}